Lanfranco Pellesi
Odense, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Substance P and PACAP activate dural mast cells through MRGPRX2, not NK1R or PAC1/VPAC receptors.
Journal: Cephalalgia : an international journal of headache
Published: August 21, 2026
Medication-overuse headache in migraine: could GLP-1 receptor agonists treat the addiction-like phenotype?
Journal: Expert opinion on pharmacotherapy
Published: August 07, 2026
Innovation is not enough: lessons from lasmiditan for real-world effectiveness in acute migraine therapy.
Journal: Expert review of neurotherapeutics
Published: July 08, 2026
Dopaminergic Dysregulation in Migraine: From Hypothalamic A11 Dysfunction to a Systemic Biobehavioral Phenotype.
Journal: International journal of molecular sciences
Published: June 24, 2026
Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.
Journal: Expert opinion on emerging drugs
Published: June 14, 2026
Impact of semaglutide introduction on the use of triptans: an interrupted-time series.
Journal: The journal of headache and pain
Published: June 04, 2026
Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.
Journal: The journal of headache and pain
Published: April 21, 2026
Editorial: Research on the correlative mechanisms and clinical exploration of headache and cerebrovascular diseases.
Journal: Frontiers in neuroscience
Published: April 06, 2026
Where are the men? A systematic review of sex bias in human provocation models of migraine.
Journal: Cephalalgia : an international journal of headache
Published: March 06, 2026
Calcitonin Gene-Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review.
Journal: Drug and alcohol review
Published: February 22, 2026
Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives.
Journal: Expert review of neurotherapeutics
Published: January 24, 2026
Last Updated: 09/26/2026